6
Participants
Start Date
May 31, 2010
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
Eculizumab
Subjects received eculizumab intravenously at the time of transplant, on the day after transplant, then weekly for four weeks. At four weeks post transplant, anti-blood group antibody levels were determined. Subjects may have potentially received eculizumab every two weeks for one year depending on antibody levels.
Mayo Clinic, Rochester
Lead Sponsor
Collaborators (1)
Alexion Pharmaceuticals, Inc.
INDUSTRY
Mayo Clinic
OTHER